GSK to launch Paxil CR in July

GSK unveiled its plan to launch Paxil (paroxetine HCl) controlled release tablet (12.5 mg) in July, which belongs to a class of the selective serotonin reuptake inhibitors (SSRIs) having broad range of efficacy in mood and anxiety disorders, including major depressive disorders, panic disorder, generalized anxiety disorder, obsessive-compulsive disorder, and premenstrual dysphoric disorder.

...